Skip to main content
Autobound logo
Merck10-Q: Market expansion

Merck seeking approval for Keytruda and Welireg in Japan and the EU to drive international growth.

Read at SEC EDGAR

What happened

Merck is actively pursuing market expansion for its key oncology drugs, with Keytruda and Welireg under regulatory review in Japan and the EU.

Source

SEC EDGARMay 4, 2026

Quarterly report (Form 10-Q)

Merck 10-Q

Filing excerpt

Keytruda is under review in Japan in combination with chemotherapy...

sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Market expansion

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
03/31
Filed
May 4, 2026

More from Merck

Company page →

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
310158
Accession number
0001628280-26-029802
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Scaling infrastructure needed

Topics and mentions

Regions named

  • Japan
  • EU

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
May 5, 2026
signal_type
sec-10q
signal_subtype
marketExpansion

Use this data

Get every 10-Q signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/476a8a14-fc6f-4c80-988b-67cc889132a6 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "476a8a14-fc6f-4c80-988b-67cc889132a6",
  "signal_type": "sec-10q",
  "signal_subtype": "marketExpansion",
  "detected_at": "2026-05-05T08:48:22.609+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "Merck is actively pursuing market expansion for its key oncology drugs, with Keytruda and Welireg under regulatory review in Japan and the EU. This international push requires investment in regional sales infrastructure, marketing localization, and navigating different regulatory and reimbursement landscapes, creating vendor opportunities.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "Merck seeking approval for Keytruda and Welireg in Japan and the EU to drive international growth.",
    "excerpts": "Keytruda is under review in Japan in combination with chemotherapy...",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm",
    "filing_date": "2026-05-04",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Scaling infrastructure needed",
    "signal_category": "market",
    "regions_mentioned": [
      "Japan",
      "EU"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.